Efficacy of transjugular intrahepatic portosystemic shunt in treatment of hepatocellular carcinoma comorbid with esophagogastric variceal bleeding

Xiang GAO; Xiaofeng ZHANG; Yimin CAO; Jinjun CHEN; Xiaoqin LUO

doi:10.12449/JCH241016

Volume 40 Issue 10

Oct. 2024

Turn off MathJax

Article Contents

Abstract

References

Article Navigation > Journal of Clinical Hepatology > 2024 > 40(10): 2027-2033

PDF( 1038 KB)

Efficacy of transjugular intrahepatic portosystemic shunt in treatment of hepatocellular carcinoma comorbid with esophagogastric variceal bleeding

DOI: 10.12449/JCH241016

Xiang GAO¹,
Xiaofeng ZHANG^{1, 2},
Yimin CAO¹,
Jinjun CHEN^{1, 2, 3
,
,
,},
Xiaoqin LUO^{1, 2
,
,
,}

1.
Hepatology Unit，Nanfang Hospital，Southern Medical University，Guangzhou 510515，China
2.
Department of Hepatology，Zengcheng Branch of Nanfang Hospital，Southern Medical University，Guangzhou 511300，China
3.
Hepatology Institute of Guangdong Province，Guangzhou 510515，China

Research funding:

National Natural Science Foundation of China (82300698);

National Natural Science Foundation of China (82370614)

More Information

Corresponding author: CHEN Jinjun， chjj@smu.edu.cn （ORCID： 0000-0003-4275-9149）; LUO Xiaoqin， lingdu618@126.com （ORCID： 0009-0002-3907-1087）
Received Date: 2024-01-12
Accepted Date: 2024-03-04
Published Date: 2024-10-25

Abstract

Abstract

Objective To investigate the efficacy of transjugular intrahepatic portosystemic shunt （TIPS） in preventing rebleeding in patients with hepatocellular carcinoma （HCC） comorbid with esophagogastric variceal bleeding and the influencing factors for prognosis. Methods A retrospective analysis was performed for the clinical data of 35 HCC patients comorbid with esophagogastric variceal bleeding who were admitted to Zengcheng Branch of Nanfang Hospital， Southern Medical University， and were treated with TIPS from July 2019 to April 2023. The Kaplan-Meier curve was used to assess rebleeding rate and survival rate after TIPS， and the Cox regression model was used to investigate the influencing factors for postoperative rebleeding and survival. Results The TIPS procedure was technically successful in all patients， with a median follow-up time of 16.4 months. During follow-up， 11 patients （31.4%） experienced esophagogastric variceal rebleeding， with the 1-month， 3-month， and 1-year rebleeding rates of 5.7%， 17.1%， and 28.6%， respectively. White blood cell count （WBC）（risk ratio ［HR］=1.31， 95% confidence interval ［CI］： 1.04 ‍—‍ 1.64， P=0.021）， number of tumors ≥3 （HR=35.68， 95%CI： 1.74 ‍—‍ 733.79， P=0.021）， and portal pressure gradient before TIPS （HR=0.85， 95%CI： 0.73 ‍—‍ 0.99， P=0.032） were independent predictive factors for rebleeding after TIPS. Shunt dysfunction was observed in 5 patients after surgery. A total of 19 patients died during follow-up， with a median survival time of 9.6 months. Portal vein tumor thrombosis （PVTT）（HR=7.04， 95%CI： 1.31 ‍—‍ 37.78， P=0.023）， total bilirubin （TBil）（HR=1.02， 95%CI： 1.00 ‍—‍ 1.03， P=0.042）， and serum albumin （HR=0.82， 95%CI： 0.72 ‍—‍ 0.94， P=0.004） were independent predictive factors for survival after TIPS. Conclusion TIPS procedure can be used as a therapeutic option to prevent esophagogastric variceal rebleeding in patients with HCC. Patients with a relatively high level of WBC or TBil or those with PVTT tend to have a poorer prognosis， and the application of TIPS treatment in such patients should be determined with caution.
- Carcinoma， Hepatocellular,
- Portasystemic Shunt， Transjugular Intrahepatic,
- Esophageal and Gastric Varices,
- Hemorrhage

FullText(HTML)

References(32)

References

[1]	GINÈS P, KRAG A, ABRALDES JG, et al. Liver cirrhosis[J]. Lancet, 2021, 398( 10308): 1359- 1376. DOI: 10.1016/S0140-6736(21)01374-X.
[2]	European Association for the Study of the Liver. EASL clinical practice guidelines for the management of patients with decompensated cirrhosis[J]. J Hepatol, 2018, 69( 2): 406- 460. DOI: 10.1016/j.jhep.2018.03.024.
[3]	de FRANCHIS R, FACULTY BV. Expanding consensus in portal hypertension: Report of the Baveno VI Consensus Workshop: Stratifying risk and individualizing care for portal hypertension[J]. J Hepatol, 2015, 63( 3): 743- 752. DOI: 10.1016/j.jhep.2015.05.022.
[4]	GIANNINI EG, RISSO D, TESTA R, et al. Prevalence and prognostic significance of the presence of esophageal varices in patients with hepatocellular carcinoma[J]. Clin Gastroenterol Hepatol, 2006, 4( 11): 1378- 1384. DOI: 10.1016/j.cgh.2006.08.011.
[5]	GARCIA-TSAO G, ABRALDES JG, BERZIGOTTI A, et al. Portal hypertensive bleeding in cirrhosis: Risk stratification, diagnosis, and management: 2016 practice guidance by the American Association for the study of liver diseases[J]. Hepatology, 2017, 65( 1): 310- 335. DOI: 10.1002/hep.28906.
[6]	DARIUSHNIA SR, HASKAL ZJ, MIDIA M, et al. Quality improvement guidelines for transjugular intrahepatic portosystemic shunts[J]. J Vasc Interv Radiol, 2016, 27( 1): 1- 7. DOI: 10.1016/j.jvir.2015.09.018.
[7]	LIU L, ZHAO Y, QI XS, et al. Transjugular intrahepatic portosystemic shunt for symptomatic portal hypertension in hepatocellular carcinoma with portal vein tumor thrombosis[J]. Hepatol Res, 2014, 44( 6): 621- 630. DOI: 10.1111/hepr.12162.
[8]	ZHOU J, SUN HC, WANG Z, et al. Guidelines for the diagnosis and treatment of primary liver cancer(2022 edition)[J]. Liver Cancer, 2023, 12( 5): 405- 444. DOI: 10.1159/000530495.
[9]	LYU Y, FAN DM, HAN GH. Application status and future prospect of transjugular intrahepatic portosystemic shunt in gastroesophageal variceal bleeding in liver cirrhosis[J]. J Clin Hepatol, 2022, 38( 6): 1229- 1233. DOI: 10.3969/j.issn.1001-5256.2022.06.004. 吕勇, 樊代明, 韩国宏. 经颈静脉肝内门体分流术在肝硬化食管胃底静脉曲张破裂出血中的应用现状与未来展望[J]. 临床肝胆病杂志, 2022, 38( 6): 1229- 1233. DOI: 10.3969/j.issn.1001-5256.2022.06.004.
[10]	GUPTA VF, AGASSI A, MARTIN JG, et al. Intravascular ultrasound guidance for transjugular intrahepatic portosystemic shunt creation reduces laboratory markers of acute liver injury[J]. J Vasc Interv Radiol, 2023, 34( 10): 1680- 1689. e 2. DOI: 10.1016/j.jvir.2023.06.034.
[11]	ZHANG XW, TSAUO J, TIE J, et al. Emergent transjugular intrahepatic portosystemic shunt creation for acute gastric variceal bleeding in patients with hepatocellular carcinoma[J]. J Vasc Interv Radiol, 2022, 33( 6): 702- 706. DOI: 10.1016/j.jvir.2022.03.012.
[12]	TSAUO J, TIE J, XUE H, et al. Transjugular intrahepatic portosystemic shunt creation for the prevention of gastric variceal rebleeding in patients with hepatocellular carcinoma: A multicenter retrospective study[J]. J Vasc Interv Radiol, 2021, 32( 7): 963- 969. DOI: 10.1016/j.jvir.2021.04.005.
[13]	LIU JC, MA JQ, ZHOU C, et al. Potential benefits of underdilation of 8-mm covered stent in transjugular intrahepatic portosystemic shunt creation[J]. Clin Transl Gastroenterol, 2021, 12( 6): e00376. DOI: 10.14309/ctg.0000000000000376.
[14]	CAO LM, ZHANG YX, LIANG ZH, et al. Clinical efficacy of repeated TACE combined with TIPS in treatment of patients with hepatocellular carcinoma complicated by liver cirrhosis and upper gastrointestinal bleeding[J]. Clin Misdiagn Misther, 2022, 35( 2): 39- 43. DOI: 10.3969/j.issn.1002-3429.2022.02.010. 曹莉明, 张勇学, 梁志会, 等. 多次TACE联合TIPS治疗肝癌合并肝硬化上消化道出血的临床效果[J]. 临床误诊误治, 2022, 35( 2): 39- 43. DOI: 10.3969/j.issn.1002-3429.2022.02.010.
[15]	Chinese Society of Spleen and Portal Hypertension Surgery, Chinese Society of Surgery, Chinese Medical Association. Chinese expert consensus on clinical diagnosis and treatment of portal hypertension with hepatocellular carcinoma(2022 edition)[J]. Chin J Dig Surg, 2022, 21( 4): 444- 455. DOI: 10.3760/cma.j.cn115610-20220223-00104. 中华医学会外科学分会脾及门静脉高压外科学组. 门静脉高压合并肝细胞癌临床诊断与治疗中国专家共识(2022版)[J]. 中华消化外科杂志, 2022, 21( 4): 444- 455. DOI: 10.3760/cma.j.cn115610-20220223-00104.
[16]	WU WY, ZHANG FM, MEI XC, et al. Balloon-compression endoscopic injection sclerotherapy versus transjugular intrahepatic portosystemic shunt for esophageal variceal rebleeding[J]. Surg Endosc, 2023, 37( 7): 5766- 5774. DOI: 10.1007/s00464-023-10085-y.
[17]	XUE H, ZHANG M, PANG JX, et al. Transjugular intrahepatic portosystemic shunt vs endoscopic therapy in preventing variceal rebleeding[J]. World J Gastroenterol, 2012, 18( 48): 7341- 7347. DOI: 10.3748/wjg.v18.i48.7341.
[18]	LIU JC, SHI Q, XIAO SP, et al. Using transjugular intrahepatic portosystemic shunt as the first-line therapy in secondary prophylaxis of variceal hemorrhage[J]. J Gastroenterol Hepatol, 2020, 35( 2): 278- 283. DOI: 10.1111/jgh.14761.
[19]	RIPOLL C, GENESCÀ J, ARAUJO IK, et al. Rebleeding prophylaxis improves outcomes in patients with hepatocellular carcinoma. A multicenter case-control study[J]. Hepatology, 2013, 58( 6): 2079- 2088. DOI: 10.1002/hep.26629.
[20]	AUGUSTIN S, MUNTANER L, ALTAMIRANO JT, et al. Predicting early mortality after acute variceal hemorrhage based on classification and regression tree analysis[J]. Clin Gastroenterol Hepatol, 2009, 7( 12): 1347- 1354. DOI: 10.1016/j.cgh.2009.08.011.
[21]	CHEN J, TSENG Y, LUO TC, et al. Prophylactic endoscopic therapy for variceal bleeding in patients with hepatocellular carcinoma[J]. J Cancer, 2019, 10( 14): 3087- 3093. DOI: 10.7150/jca.30434.
[22]	LEE YR, PARK SY, TAK WY. Treatment outcomes and prognostic factors of acute variceal bleeding in patients with hepatocellular carcinoma[J]. Gut Liver, 2020, 14( 4): 500- 508. DOI: 10.5009/gnl19155.
[23]	KAWAI T, YASHIMA Y, SUGIMOTO T, et al. Emergency endoscopic variceal ligation following variceal rupture in patients with advanced hepatocellular carcinoma and portal vein tumor thrombosis: A retrospective study[J]. World J Surg Oncol, 2016, 14: 52. DOI: 10.1186/s12957-016-0802-z.
[24]	LIANG XX, HE LL, YANG JR, et al. Risk factors of rebleeding after endoscopic treatment of patients with portal vein tumor thrombus and esophagogastric variceal bleeding[J]. J Clin Hepatol, 2022, 38( 10): 2290- 2295. DOI: 10.3969/j.issn.1001-5256.2022.10.017. 梁秀霞, 何玲玲, 杨君茹, 等. 内镜治疗肝细胞癌合并门静脉癌栓患者食管胃静脉曲张出血后再出血的危险因素分析[J]. 临床肝胆病杂志, 2022, 38( 10): 2290- 2295. DOI: 10.3969/j.issn.1001-5256.2022.10.017.
[25]	CHANG CJ, HOU MC, LIAO WC, et al. Risk factors of early re-bleeding and mortality in patients with ruptured gastric varices and concomitant hepatocellular carcinoma[J]. J Gastroenterol, 2012, 47( 5): 531- 539. DOI: 10.1007/s00535-011-0518-3.
[26]	WALLACE M, SWAIM M. Transjugular intrahepatic portosystemic shunts through hepatic neoplasms[J]. J Vasc Interv Radiol, 2003, 14( 4): 501- 507. DOI: 10.1097/01.rvi.0000064846.87207.ab.
[27]	FONIO P, DISCALZI A, CALANDRI M, et al. Incidence of hepatic encephalopathy after transjugular intrahepatic portosystemic shunt(TIPS) according to its severity and temporal grading classification[J]. Radiol Med, 2017, 122( 9): 713- 721. DOI: 10.1007/s11547-017-0770-6.
[28]	LIU MY, LI WZ, LI PJ, et al. Comparison of endoscopic therapy and TIPS in prophylaxis and treatment of variceal bleeding in decompensated portal hypertension[J]. J Clin Hepatol, 2023, 39( 7): 1529- 1534. DOI: 10.3969/j.issn.1001-5256.2023.07.003. 刘梦莹, 李伟之, 李培杰, 等. 失代偿期门静脉高压并发食管胃静脉曲张出血的防治: 内镜vs经颈静脉肝内门体分流术[J]. 临床肝胆病杂志, 2023, 39( 7): 1529- 1534. DOI: 10.3969/j.issn.1001-5256.2023.07.003.
[29]	ZHENG MH, CHEN YP, BAI JL, et al. Transjugular intrahepatic portosystemic shunt versus endoscopic therapy in the secondary prophylaxis of variceal rebleeding in cirrhotic patients: Meta-analysis update[J]. J Clin Gastroenterol, 2008, 42( 5): 507- 516. DOI: 10.1097/MCG.0b013e31815576e6.
[30]	BAI M, QI XS, YANG ZP, et al. Predictors of hepatic encephalopathy after transjugular intrahepatic portosystemic shunt in cirrhotic patients: A systematic review[J]. J Gastroenterol Hepatol, 2011, 26( 6): 943- 951. DOI: 10.1111/j.1440-1746.2011.06663.x.
[31]	NARDELLI S, GIOIA S, PASQUALE C, et al. Cognitive impairment predicts the occurrence of hepatic encephalopathy after transjugular intrahepatic portosystemic shunt[J]. Am J Gastroenterol, 2016, 111( 4): 523- 528. DOI: 10.1038/ajg.2016.29.
[32]	BERLIOUX P, ROBIC MA, POIRSON H, et al. Pre-transjugular intrahepatic portosystemic shunts(TIPS) prediction of post-TIPS overt hepatic encephalopathy: The critical flicker frequency is more accurate than psychometric tests[J]. Hepatology, 2014, 59( 2): 622- 629. DOI: 10.1002/hep.26684.

Relative Articles

[1]	Xiaoqin ZHU, Na WEI, Yong XIAO, Baoping YU. Impact of hepatocellular carcinoma on the prognosis of patients with liver cirrhosis undergoing emergency endoscopic therapy due to esophagogastric variceal bleeding[J]. Journal of Clinical Hepatology, 2025, 41(2): 277-283. doi: 10.12449/JCH250213
[2]	Qin YIN, Zhaorong WU, Feng ZHANG, Chunyan JIN, Yanping CAO, Jiangqiang XIAO, Yuzheng ZHUGE, Qian WANG. Risk factors for unplanned readmission after transjugular intrahepatic portosystemic shunt in cirrhotic patients with esophagogastric variceal bleeding and construction of a nomogram model[J]. Journal of Clinical Hepatology, 2024, 40(9): 1796-1801. doi: 10.12449/JCH240913
[3]	Xinyi LI, Jiaojiao LI, Wei SUN. Establishment and evaluation of a nomogram prediction model for overt hepatic encephalopathy after transjugular intrahepatic portosystemic shunt in patients with liver cirrhosis and esophagogastric variceal bleeding[J]. Journal of Clinical Hepatology, 2024, 40(8): 1605-1611. doi: 10.12449/JCH240816
[4]	Mengying LIU, Weizhi LI, Peijie LI, Fuquan MA, Yuling CHEN, Huanhuan SUN, Tiantian GAO, Hui XUE. Comparison of endoscopic therapy and TIPS in prophylaxis and treatment of variceal bleeding in decompensated portal hypertension[J]. Journal of Clinical Hepatology, 2023, 39(7): 1529-1534. doi: 10.3969/j.issn.1001-5256.2023.07.003
[5]	Henglu BIAN, Jiasu LI, Cui LIU, Feng LIU. An excerpt of AASLD practice guidance on the use of TIPS， variceal embolization， and retrograde transvenous obliteration in the management of variceal hemorrhage in 2023[J]. Journal of Clinical Hepatology, 2023, 39(11): 2564-2568. doi: 10.3969/j.issn.1001-5256.2023.11.008
[6]	Qiong WU, Lianhui ZHAO, Guangchuan WANG, Chunqing ZHANG. Transjugular intrahepatic portosystemic shunt combined with collateral vessel embolization in treatment of gastroesophageal variceal bleeding in liver cirrhosis： Research advances and controversies[J]. Journal of Clinical Hepatology, 2023, 39(10): 2460-2463. doi: 10.3969/j.issn.1001-5256.2023.10.026
[7]	Qingjuan HE, Yingxia FANG, Xuchen LIU, Zhongbin LI. Risk factors for rebleeding after emergency esophageal variceal ligation in patients with liver cirrhosis[J]. Journal of Clinical Hepatology, 2022, 38(8): 1801-1805. doi: 10.3969/j.issn.1001-5256.2022.08.016
[8]	Xiuxia LIANG, Lingling HE, Junru YANG, Fuyang ZHANG, Jiali MA, Yuling ZHOU, Julong HU, Ping LI, Hongshan WEI. Risk factors of rebleeding after endoscopic treatment of patients with portal vein tumor thrombus and esophagogastric variceal bleeding[J]. Journal of Clinical Hepatology, 2022, 38(10): 2290-2295. doi: 10.3969/j.issn.1001-5256.2022.10.017
[9]	Qun ZHANG, ke SHI, Xianbo WANG. Developing the prediction model of esophagogastric variceal rebleeding in patients with liver cirrhosis based on artificial neural network[J]. Journal of Clinical Hepatology, 2022, 38(11): 2493-2498. doi: 10.3969/j.issn.1001-5256.2022.11.011
[10]	Yan ZHANG, Huiguo DING. Risk factors for early rebleeding after endoscopic therapy for esophageal varices in cirrhotic patients[J]. Journal of Clinical Hepatology, 2021, 37(9): 2087-2091. doi: 10.3969/j.issn.1001-5256.2021.09.017
[11]	Yingying CAO, Tao HAN, Yu ZHANG, Fang LIU, Jing LIANG, Haixia YUAN, Jun LI, Huiling XIANG. Rebleeding and prognosis of patients with liver cirrhosis and severe esophagogastric variceal bleeding[J]. Journal of Clinical Hepatology, 2021, 37(6): 1326-1330. doi: 10.3969/j.issn.1001-5256.2021.06.022
[12]	Li LI, Pengpeng DING, Jianhong CHEN, Yadan WANG, Chunmei GUO, Mingming MENG, Yanling WANG, Xiaobao QI, Wenhui ZHANG, Hong LIU. Influencing factors for the clinical effect of emergency endoscopic therapy in treatment of acute-on-chronic liver failure with gastroesophageal variceal bleeding[J]. Journal of Clinical Hepatology, 2021, 37(5): 1142-1146. doi: 10.3969/j.issn.1001-5256.2021.05.032
[13]	Lu Zheng, Jin Bo, Zhang WenHui, Zhang JunHua, Chi ChunSheng, Wu LiBing, Yan LiPing, Liu Bo, Han JingJing, Ma XueMei, Wang YanLing, Han Jun, Yu XiaoLi, Wu Qin, Duan XueZhang, Li HanWei. Clinical application of hepatic venous pressure gradient measurement after esophagogastric variceal bleeding in guiding secondary prevention for patients with liver cirrhosis[J]. Journal of Clinical Hepatology, 2020, 36(1): 107-112. doi: 10.3969/j.issn.1001-5256.2020.01.024
[14]	Ma JiaLi, Chen Xu, He LingLing, Wei HongShan, Li Ping. Value of Child-Pugh score,Model for End-Stage Liver Disease score,MELD combined with serum sodium concentration,APASAL score,and R-score in predicting rebleeding and death in cirrhotic patients with esophagogastric variceal bleeding[J]. Journal of Clinical Hepatology, 2020, 36(6): 1278-1283. doi: 10.3969/j.issn.1001-5256.2020.06.018
[15]	Ai ZhengLin, Hong Shan, Hu JuLong, Li Ping, Zhou YuLing, Liang XiuXia. Establishment and evaluation of a predictive model for rebleeding after endoscopic treatment of esophageal and gastric varices[J]. Journal of Clinical Hepatology, 2019, 35(9): 1954-1957. doi: 10.3969/j.issn.1001-5256.2019.09.014
[16]	Lin FanYu, Huang Hua, Lu MingLiang. Research advances in prognostic factors for patients with esophagogastric variceal bleeding[J]. Journal of Clinical Hepatology, 2018, 34(11): 2428-2432. doi: 10.3969/j.issn.1001-5256.2018.11.036
[17]	He Yang, Su YaRong, Han ZiYan. Current status of research on primary and secondary risk factors for esophagogastric variceal rebleeding in patients with liver cirrhosis[J]. Journal of Clinical Hepatology, 2018, 34(7): 1555-1559. doi: 10.3969/j.issn.1001-5256.2018.07.041
[18]	Peng Zhong, Qi XingShun, Guo XiaoZhong. Current status of treatment of liver cancer complicated by esophageal variceal bleeding[J]. Journal of Clinical Hepatology, 2017, 33(7): 1362-1364. doi: 10.3969/j.issn.1001-5256.2017.07.035
[19]	Liu TieJun. Therapeutic effect and advantages of percutaneous transhepatic variceal embolization in treatment of variceal rupture and bleeding after devascularization: an analysis of 34 cases[J]. Journal of Clinical Hepatology, 2015, 31(11): 1867-1869. doi: 10.3969/j.issn.1001-5256.2015.11.023
[20]	Gu Chuan, Li Lu, Wang Jun, Hou FengQin, Xu XiaoYuan. Study on efficacy of endoscopic ligation therapy for esophageal varices and risk factors for postoperative rebleeding[J]. Journal of Clinical Hepatology, 2014, 30(12): 1279-1282. doi: 10.3969/j.issn.1001-5256.2014.12.011

Supplements(0)

Cited By

Proportional views

Proportional views

通讯作者: 陈斌, bchen63@163.com

1.
沈阳化工大学材料科学与工程学院沈阳 110142

Figures(2) / Tables(3)

Get Citation

PDF

XML

Article Metrics

Article views (428) PDF downloads(28)

Efficacy of transjugular intrahepatic portosystemic shunt in treatment of hepatocellular carcinoma comorbid with esophagogastric variceal bleeding

DOI: 10.12449/JCH241016

Abstract

References

Relative Articles

Proportional views

Catalog

通讯作者: 陈斌, bchen63@163.com

Article Metrics

Proportional views

Related

Efficacy of transjugular intrahepatic portosystemic shunt in treatment of hepatocellular carcinoma comorbid with esophagogastric variceal bleeding

DOI: 10.12449/JCH241016

Abstract

References

Relative Articles

Proportional views

Catalog

通讯作者: 陈斌, bchen63@163.com

Article Metrics

Proportional views

Related

About Journal

Submission Guideline

Journal Online

Hepatobiliary College

Guidelines

Export File

Citation

Format

Content